Pharmacological benefits of Acacia against metabolic diseases: intestinal-level bioactivities and favorable modulation of gut microbiota

Context Obesity-associated chronic metabolic disease is a leading contributor to mortality globally. Plants belonging to the genera Acacia are routinely used for the treatment of diverse metabolic diseases under different ethnomedicinal practices around the globe. Objective The current review centres around the pharmacological evidence of intestinal-level mechanisms for metabolic health benefits by Acacia spp. Results Acacia spp. increase the proportions of gut commensals (Bifidobacterium and Lactobacillus) and reduces the population of opportunistic pathobionts (Escherichia coli and Clostridium). Acacia gum that is rich in fibre, can also be a source of prebiotics to improve gut health. The intestinal-level anti-inflammatory activities of Acacia are likely to contribute to improvements in gut barrier function that would prevent gut-to-systemic endotoxin translocation and limit low-grade inflammation associated with metabolic diseases. Conclusion This comprehensive review for the first time has emphasised the intestinal-level benefits of Acacia spp. which could be instrumental in limiting the burden of metabolic disease.

Automated summary

Plants belonging to the genera Acacia have shown potential benefits for metabolic health at the intestinal level including increasing beneficial gut bacteria and reducing harmful pathogens, providing anti-inflammatory effects and potentially improving gut barrier function to prevent endotoxin translocation and limit low-grade inflammation associated with metabolic diseases.